Introduction
============

Henoch-Schönlein purpura (HSP) is the most common type of systemic small-vessel vasculitis in pediatric patients, and is associated with multiple and complex pathogenic factors, as well as diverse pathological damage ([@b1-etm-0-0-7038]). It is a systemic disorder characterized by leukocytoclastic vasculitis involving the capillaries and deposition of immunoglobulin (Ig)A immune complexes ([@b2-etm-0-0-7038]). Of all pediatric patients with HSP, \>90% are \<10 years old ([@b3-etm-0-0-7038],[@b4-etm-0-0-7038]). Between weeks 4 and 6 of the initial disease presentation, \~40% of pediatric patients with HSP progress to HSP nephritis (HSPN), which is one of the major manifestations and the primary cause of mortality associated with HSP ([@b2-etm-0-0-7038],[@b5-etm-0-0-7038],[@b6-etm-0-0-7038]). To date, however, the exact pathophysiology of HSPN has remained largely elusive and requires further investigation.

Long non-coding RNAs (lncRNAs) are a class of RNA with a length of \>200 nucleotides and no coding function. In recent years, as the rapid development of technologies has facilitated the analysis of the 'transcriptome' the study of lncRNAs has enabled the discovery of comprehensive genetic information in the human genome. A large amount of evidence has suggested that lncRNAs regulate protein-coding genes at the transcriptional and post-transcriptional levels, and exert transcription control ([@b7-etm-0-0-7038],[@b8-etm-0-0-7038]). Numerous studies have provided novel insight into different expression profiles of lncRNAs in a number of human kidney diseases, including acute kidney rejection, diabetic nephropathy, membranous nephropathy, chronic kidney disease and lupus nephritis ([@b9-etm-0-0-7038]--[@b15-etm-0-0-7038]). In parallel with their role in disease pathogenesis, lncRNAs may also serve as a potential biomarker of disease status and aid in the diagnosis, prognosis and clinical management of disease ([@b16-etm-0-0-7038],[@b17-etm-0-0-7038]). However, the expression patterns and functions of lncRNAs in HSPN have largely remained to be elucidated.

In the present study, high-throughput sequencing was applied to identify 820 lncRNAs and 3,557 mRNAs that are significantly aberrantly expressed in the peripheral blood of pediatric patients with HSPN. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) provided results that were consistent with those obtained by data analysis of the gene expression profiles, thereby verifying them. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were then performed to elucidate the roles and pathways of the differentially expressed RNAs. These results indicated that the aberrantly expressed RNAs may have important roles in the development of HSPN through promoting serum proteins generation and regulating the apoptosis pathway, and that knowing the differently expressed RNAs might provide useful biomarkers for HSPN therapy and diagnosis.

Patients and methods
====================

### Patients and sample collection

A total of 6 pediatric patients with HSPN (4 males and 2 females; mean age, 12.17±1.72 years) were recruited at the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine (Shenyang, China) between November 2016 and March 2017. The diagnostic criteria for HSPN were according to those outlined at the Congress of the Chinese Pediatric Society in 2000 ([@b18-etm-0-0-7038]). Patients with other coexisting renal pathologies were excluded. None of the patients of the present study was diagnosed with any other complications. Furthermore, none of the subjects had taken any hormonal or immunosuppressive drugs for ≥6 months prior to the commencement of the study. The clinical characteristics of the patients with HSPN are presented in [Table I](#tI-etm-0-0-7038){ref-type="table"}. The mean urine red blood cell count, 24-h urine protein quantity and serum IgA were 387.48±590.34 p/µl, 0.28±0.15 g/24 h and 3.00±1.21 g/l, respectively. A total of 4 age matched healthy subjects (1 male and 3 females; mean age, 11.25±2.99 years) were selected as healthy controls (HC). Blood samples were obtained from the 6 children with HSPN and 4 healthy volunteers.

The present study was approved by the Ethics Committee of the Institutional Ethics Board of the Affiliated Hospital of Liaoning University of Traditional Chinese Medicine (approval no. 2016CS(KT)-002-01). Written informed consent was obtained from the parents of all of the pediatric subjects enrolled in the present study.

### RNA extraction and library construction

Peripheral blood was obtained from the subjects of the groups and collected in tubes containing EDTA as an anticoagulant. Peripheral blood total RNA was isolated using a total RNA isolation kit purchased from BioTeke Corp. (Beijing, China), according to the manufacturer\'s protocols. From the RNA (1 µg) the ribosomal (r)RNA was removed using a Ribo-Zero rRNA Removal kit (Illumina, Inc., San Diego, CA, USA), according to the manufacturer\'s protocols. RNA libraries were constructed using rRNA-depleted RNAs with a TruSeq Stranded Total RNA Library Prep kit (Illumina, Inc.), according to the manufacturer\'s protocols. Libraries were controlled for quality and were quantified using a BioAnalyzer 2100 system (Agilent Technologies, Inc., Santa Clara, CA, USA).

### High-throughput sequencing and computational analysis

A DNA library (420 µl of a 10 pM library) was denatured as single-stranded DNA molecules, captured on Illumina flow cells, amplified *in situ* as clusters and finally sequenced for 150 cycles on an Illumina Hiseq Sequencer, according to the manufacturer\'s protocols. High-throughput sequencing was performed by Shanghai Cloud-Seq Biotech, Inc., (Shanghai, China). In brief, paired-end reads were harvested from the Illumina HiSeq 2000 sequencer (Illumina, Inc.), and were quality controlled via their Q score (\>Q30). Following 3′ adaptor-trimming and removal of low-quality reads with cutadapt software (v1.9.3) ([@b19-etm-0-0-7038]), the high-quality, trimmed reads were aligned to a reference genome (UCSC HG19) guided by the Ensembl GFF gene annotation file with hisat2 software (v2.0.4; <http://ccb.jhu.edu/software/hisat2/index.shtml>). Next, cuffdiff software (v2.2.1, part of cufflinks; <http://cufflinks.cbcb.umd.edu/>) was used to obtain the gene fragment counts per kilobase of exon per million fragments mapped (FPKM) as the expression profiles of lncRNA and mRNA, and the fold change (FC) and P-value were calculated based on the FPKM, from which differentially expressed lncRNAs and mRNAs were identified.

### GO term analysis and pathway analysis

The GO ([www.geneontology.org](www.geneontology.org)) and KEGG ([www.genome.ad.jp/kegg](www.genome.ad.jp/kegg)) databases were utilized to analyze biological functions and signaling pathways based on the differentially expressed lncRNAs and mRNAs. Fisher\'s exact test was used to determine whether there was more overlap between the gene list and the GO annotation list than that expected to occur by chance. The P-value denoted the significance of the GO term enrichment and was the basis of the significance level, with P\<0.05 set as the threshold. Pathway analysis was used to investigate the major pathways of the aberrantly expressed genes according to the KEGG database. The threshold for the false discovery rate was set at 0.05, and P\<0.05 was considered to indicate a statistically significant difference.

### RT-qPCR validation

Total RNA was extracted from the peripheral blood using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA), according to the manufacturer\'s protocols. In brief, 1 µg total RNA from each sample was used for the synthesis of first strand complementary DNA using a SuperScript^™^ III First-Strand Synthesis System kit (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer\'s instructions. qPCR was performed on an Applied Biosystems ViiA^™^ 7 Real-time PCR System using the SYBR-Green method (both Thermo Fisher Scientific, Inc.), according to the manufacturer\'s protocol. The thermocycling conditions were as follows: A denaturation step at 95°C for 10 min, followed by 40 cycles of 95°C for 10 sec and 60°C for 60 sec. The primer sequences are presented in [Table II](#tII-etm-0-0-7038){ref-type="table"}. Relative gene expression levels were quantified using the 2^−∆∆Cq^ method, in which β-actin (ACTB) was used as an internal control ([@b20-etm-0-0-7038]).

### Statistical analysis

Statistical analysis and graphic presentation were performed with SPSS version 19.0 software packages (IBM Corp., Armonk, NY, USA). Measurement data are expressed as the mean ± standard deviation. The differences in expression levels of tested lncRNAs and mRNAs between two groups were assessed using Student\'s t-test. P\<0.05 was considered to indicate a statistical significant difference. FC≥1.5 indicated upregulation and \<0.67 indicated downregulation. were considered to indicate significant differences. Otherwise, the non-parametric Mann-Whitney U test was used to analyze the data. Fisher\'s exact test was used for GO analysis and KEGG pathway analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Subject characteristics

The baseline demographic and clinical data of the subjects in the HSPN group and the HC group are summarized in [Table III](#tIII-etm-0-0-7038){ref-type="table"}. The pediatric patients with HSPN had a significantly higher urine red blood cell count, 24-h urine protein quantity and serum IgA than the HC group.

### Differentially expressed lncRNAs

A total of 820 lncRNAs were aberrantly expressed between the HSPN group and the HC group. High-throughput sequencing revealed that 34 lncRNAs were upregulated and 786 lncRNAs were downregulated. The top 25 differentially expressed lncRNAs according to their FC values in the HSPN vs. HC group are presented in [Table IV](#tIV-etm-0-0-7038){ref-type="table"}. Hierarchical clustering was performed according to the lncRNA expression levels in these 10 samples ([Fig. 1A](#f1-etm-0-0-7038){ref-type="fig"}). Scatter and volcano plots were used to assess variations in lncRNA expression between the two groups ([Fig. 1B and C](#f1-etm-0-0-7038){ref-type="fig"}, respectively).

### Differentially expressed mRNAs

A total of 3,557 mRNAs that were aberrantly expressed between the two groups were identified using the same criteria as those for the lncRNAs. A total of 1,232 upregulated and 2,325 downregulated differentially expressed mRNAs were identified. The top 25 differentially expressed mRNAs are listed in [Table V](#tV-etm-0-0-7038){ref-type="table"}. Hierarchical clustering was performed according to the mRNA expression levels in all 10 samples ([Fig. 2A](#f2-etm-0-0-7038){ref-type="fig"}). Scatter and volcano plots generated from these differentially expressed mRNAs exhibited a clear segregation between the HSPN and HC groups ([Fig. 2B and C](#f2-etm-0-0-7038){ref-type="fig"}, respectively).

### Validation of sequencing data using RT-qPCR

In order to validate the sequencing analysis, 6 differentially expressed lncRNAs were selected. RT-qPCR analysis verified that the lncRNA ENSG00000252310 was upregulated, while ENSG00000267121, uc001kfc.1, uc010qna.2, ENST00000378432 and ENST00000571370 were downregulated in the 10 samples ([Fig. 3](#f3-etm-0-0-7038){ref-type="fig"}). It was identified that the RT-qPCR results were consistent with the high-throughput sequencing data.

### GO and KEGG pathway enrichment analysis

To investigate potential lncRNAs and the moieties that they regulate, which are enriched in the GO terms biological process, cellular component and molecular function, GO analysis was performed for the differentially expressed lncRNAs ([Fig. 4](#f4-etm-0-0-7038){ref-type="fig"}). The present study focused on GO terms enriched among downregulated lncRNAs, and the top 10 terms in the category biological process were as follows: i) Organelle organization, ii) cell cycle process, iii) mitotic cell cycle process, iv) single-organism organelle organization, v) cell death, vi) death, vii) negative regulation of cellular process, viii) protein transmembrane transport, ix) negative regulation of biological process and x) interspecies interaction between organisms ([Fig. 4A](#f4-etm-0-0-7038){ref-type="fig"}). The top 10 GO terms in the category cellular component were as follows: i) Nucleoplasm, ii) nuclear body, iii) nuclear part, iv) cytoplasm, v) organelle part, vi) nucleoplasm part, vii) nucleus, viii) promyelocytic leukemia protein body, ix) intracellular and x) nuclear lumen ([Fig. 4B](#f4-etm-0-0-7038){ref-type="fig"}). The top 10 GO terms in the category molecular function were as follows: i) Protein binding, ii) enzyme binding, iii) identical protein binding, iv) protein domain specific binding, v) binding, vi) RNA polymerase II transcription regulatory region sequence-specific DNA binding transcription factor activity involved in positive regulation of transcription, vii) metalloendopeptidase activity, viii) protein C-terminus binding, ix) GTP-Rho binding and x) lamin binding ([Fig. 4C](#f4-etm-0-0-7038){ref-type="fig"}).

Pathway analysis indicated that 25 pathways were significantly enriched among the differentially expressed lncRNAs. The top 10 significantly enriched pathways were presented as follows: i) Measles, ii) Epstein-Barr virus infection, iii) longevity regulating pathway-multiple, iv) soluble N-ethylmaleimide sensitive factor attachment protein receptor interactions in vesicular transport, v) chronic myeloid leukemia, vi) apoptosis, vii) tight junction, viii) longevity regulating pathway-mammal, ix) hepatitis B and x) endometrial cancer ([Fig. 5A](#f5-etm-0-0-7038){ref-type="fig"}). Furthermore, the differently expressed mRNAs were also subjected to KEGG analysis, the top 10 enriched pathways for the upregulated mRNAs were presented as follows: i) Ribosome, ii) phagosome, iii) protein processing in endoplasmic reticulum, iv) leishmaniasis, v) pancreatic cancer, vi) epithelial cell signaling in *Helicobacter pylori* infection, vii) endocytosis, viii) tumor necrosis factor (TNF) signaling pathway, ix) pathogenic *Escherichia coli* infection and x) tuberculosis ([Fig. 5B](#f5-etm-0-0-7038){ref-type="fig"}). The top 11 enriched pathways for the downregulated mRNAs were presented as follows: i) Phosphatidylinositol signaling system, ii) apoptosis, iii) nuclear factor (NF)-κB signaling pathway, iv) Epstein-Barr virus infection, v) endocytosis, vi) B cell receptor signaling pathway, vii) T cell receptor signaling pathway, viii) T cell receptor signaling pathway, ix) phospholipase D signaling pathway, x) acute myeloid leukemia and xi) lysine degradation ([Fig. 5C](#f5-etm-0-0-7038){ref-type="fig"}).

Discussion
==========

HSPN is a major public health problem that accounts for 78.9% of secondary glomerulopathies in pediatric patients ([@b21-etm-0-0-7038]). Etiologically, persistent purpura or relapse, severe abdominal symptoms (abdominal pain, gastrointestinal bleeding and severe bowel angina), arthritis and being aged \>10 years old are the most significant risk factors for pediatric HSPN ([@b22-etm-0-0-7038]--[@b24-etm-0-0-7038]). Initially, lncRNAs were assumed to simply be leaky transcription noise ([@b25-etm-0-0-7038]). However, an abundance of studies have demonstrated that lncRNAs serve important roles in physiological processes and the pathophysiology of numerous diseases, participating in the regulation of DNA methylation, histone modification, basal transcription, post-transcriptional processes, directly binding proteins and protein function ([@b26-etm-0-0-7038]--[@b30-etm-0-0-7038]).

To the best of our knowledge, the present study was the first to investigate the expression profile of lncRNAs and mRNAs in patients with HSPN. Total RNA was extracted from the peripheral blood of patients and HC, and differentially expressed lncRNAs and mRNAs were identified using high-throughput sequencing, followed by verification of certain RNAs by RT-qPCR analysis. In the RT-qPCR experiments, ACTB was used as an endogenous control for normalising the expression of lncRNAs and mRNAs according to previous studies ([@b31-etm-0-0-7038]--[@b34-etm-0-0-7038]). Studies have demonstrated that ACTB is suitable reference gene in gene expression studies of human diseases when human peripheral blood as samples ([@b35-etm-0-0-7038]--[@b37-etm-0-0-7038]), and may be more stably expressed in whole blood than in peripheral blood mononuclear cells ([@b38-etm-0-0-7038]). In the present study, it was identified that the RT-qPCR results were consistent with the high-throughput sequencing data.

A total of 820 lncRNAs, including 34 upregulated and 786 downregulated ones, were identified to be differentially expressed between the two groups. In addition, 3,557 differentially expressed protein-coding mRNAs were identified from the same samples, including 1,232 upregulated and 2,325 downregulated mRNAs. The results demonstrated that the expression of lncRNAs and mRNAs in patients with HSPN were quite different from that in HC. Additionally, a greater number of lncRNAs and mRNAs were significantly downregulated than upregulated in patients with HSPN. GO and KEGG pathway analyses were used to investigate the possible mechanistic roles and pathways of lncRNAs and mRNAs in HSPN.

An integrative method involving pathway analysis was applied to identify possible functional associations between the different RNA molecules. Based on the differentially expressed mRNAs, a pathway analysis revealed via which biological functions and mechanisms they may be involved in HSPN formation. HSPN is a small-vessel form of autoimmune vasculitis caused by IgA1-mediated inflammation ([@b39-etm-0-0-7038],[@b40-etm-0-0-7038]). The results of the present study suggested that a variety of KEGG pathways, including ribosomal function, phagosome activity, protein processing in the endoplasmic reticulum and endocytosis, are significantly enriched among the upregulated mRNAs from patients with HSPN. The majority of these pathways are involved in the generation of serum proteins, including IgA. Among these associated pathways, epithelial cell signaling in *Helicobacter pylori* infection, tumor necrosis factor TNF signaling, pathogenic *Escherichia coli* infection, the phosphatidylinositol signaling system, NF-κB signaling, Epstein-Barr virus infection, the B cell receptor signaling pathway and the T cell receptor signaling pathway exhibited significant changes in upregulated and downregulated mRNAs. In line with this, Shin *et al* ([@b41-etm-0-0-7038]) reported that *Helicobacter pylori* infection may cause the serum levels of IgA, C3 and cryoglobulins to increase, which promotes immune complex formation and increases the risk of HSP occurrence. Hirayama *et al* ([@b42-etm-0-0-7038]) demonstrated that the percentage values of the CD3-gated β-chain of the T cell receptor in patients with HSPN were significantly increased compared with those in healthy individuals. Chen *et al* ([@b43-etm-0-0-7038]) revealed that TNF-like weak inducer of apoptosis, a member of the TNF family, was elevated in patients with acute-stage HSP and may act as a regulator of NF-κB activation and chemokine production in human dermal microvascular endothelial cells, promoting leucocyte migration in cutaneous vasculitis. These results indicated that aberrant IgA circulating immune complexes, as well as elevated pro-inflammatory cytokines and chemokines, are all associated with the pathogenesis of HSPN.

Previous studies have demonstrated that apoptosis is one of the most important factors for controlling inflammation in inflammatory diseases such as HSP ([@b44-etm-0-0-7038],[@b45-etm-0-0-7038]). Among the top 10 enriched pathways of the aberrantly expressed lncRNAs in the HSPN group, the present study focused on the apoptotic pathway, which serves an important role in the pathogenesis of HSPN. Yuan *et al* ([@b46-etm-0-0-7038]) suggested that IgA1 from patients with HSP may induce apoptosis of human umbilical vein endothelial cells, which may be associated with vascular endothelial injury in HSP. Ozaltin *et al* ([@b45-etm-0-0-7038]) observed a marked expression of Fas on peripheral blood neutrophils and lymphocytes in patients with HSP in the acute and the resolution phases. This suggested that increased removal of inflammatory cells through apoptosis may contribute to the early control of the inflammatory response and repair in this self-limited vasculitis. The present study revealed that ENST00000378432, ENST00000571370, uc001kfc.1 and uc010qna.2 expression was decreased in patients with HSPN and healthy controls. These lncRNAs were associated with the p53 signaling pathway and apoptosis-associated genes (AKT serine/threonine kinase 2, tumor protein 53, phosphatase and tensin homolog and FAS). Further studies on these differentially expressed lncRNAs will be performed to establish their functions in apoptosis.

The major limitation of the present study was the sample size of the patients and controls. The present results should be validated in larger cohorts. Interaction networks analyses are also required to further investigate the associations between ncRNAs, coding RNAs and proteins. Furthermore, lncRNAs and mRNAs validated to be associated with HSPN by RT-qPCR should be further investigated at the cellular level.

In conclusion, the results of the present study demonstrated a significant difference in the expression of certain lncRNAs and mRNAs between patients with HSPN and HCs. The results indicated that lncRNAs are important regulators in HSPN pathophysiological mechanisms. Functional research on these lncRNAs may be a novel and interesting research field.
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![Profiles of differentially expressed lncRNAs between the two groups. (A) Hierarchical clustering analysis of 40 lncRNAs that were aberrantly expressed between children with HSPN (sick173, sick105, sick303, sick64, sick111 and sick87) and HC (healthy460, healthy472, healthy473 and healthy475). Red and green indicate high and low relative expression, respectively. P\<0.05 was considered to indicate a statistical significant difference. FC≥1.5 indicated upregulation and \<0.67 indicated downregulation. (B) Scatter plot of aberrant expression of lncRNAs between the HSPN and HC libraries. Red indicates upregulated lncRNAs \[log~2~(HSPN/HC)\>0\], blue indicates lncRNAs with no change in expression between HSPN and HC libraries, green indicates downregulated lncRNAs \[log~2~(HSPN/HC)\<0\]. (C) Volcano plot of aberrant lncRNA expression. The vertical green lines delineate a 1.5-fold upregulation and 0.67-fold downregulation of lncRNAs, and the horizontal line represents P=0.05. Red plots on the right side represent 34 upregulated lncRNAs with FC≥1.5 and corrected P\<0.05. Red plots on the left side represent 786 down-regulated lncRNAs with FC\<0.67 and corrected P\<0.05. lncRNA, long non-coding RNA; HSPN, Henoch-Schönlein purpura nephritis; HC, healthy controls; FC, fold change; NR, nitrate reductase.](etm-17-01-0621-g00){#f1-etm-0-0-7038}

![Differential expression of mRNAs between the two groups. (A) Hierarchical clustering analysis of 40 differentially expressed mRNAs from each sample. FC≥1.5 indicated upregulation and \<0.67 indicated downregulation. (B) Scatter plot of differential expression of mRNAs between the HSPN and HC libraries. Red indicates upregulated mRNAs \[log~2~(HSPN/HC)\>0\], blue indicates mRNAs with no change in expression between HSPN and HC libraries, green indicates downregulated mRNAs \[log~2~(HSPN/HC)\<0\]. (C) Volcano plot of differential mRNA expression. The vertical green lines delineate a 1.5-fold upregulation and 0.67-fold downregulation of mRNAs, and the horizontal line represents P=0.05. Red plots on the right side represent 1,232 upregulated mRNAs with FC≥1.5 and corrected P\<0.05. Red plots on the left side represent 2,325 downregulated mRNAs with FC\<0.67 and corrected P\<0.05. HSPN, Henoch-Schönlein purpura nephritis; HC, healthy controls; FC, fold change.](etm-17-01-0621-g01){#f2-etm-0-0-7038}

![Validation of 6 randomly selected differentially expressed lncRNAs in 10 samples by reverse transcription-quantitative polymerase chain reaction. Compared with the HC, ENSG00000252310 was upregulated, and ENSG00000267121, uc001kfc.1, uc010qna.2, ENST00000378432 and ENST00000571370 were downregulated in children with HSPN. The results were consistent with those of the high-throughput sequencing analysis. \*P\<0.05 vs. HC. HSPN, Henoch-Schönlein purpura nephritis; HC, healthy controls.](etm-17-01-0621-g02){#f3-etm-0-0-7038}

![Gene Ontology analysis of distinctively expressed long non-coding RNAs in children with HSPN. (A) Top 11 terms in the category biological processes. (B) Top 10 terms in the category cellular components. (C) Top 10 terms in the category molecular function. \*P\<0.05 vs. HC. HSPN, Henoch-Schönlein purpura nephritis; HC, healthy controls; PML, promyelocytic leukemia protein.](etm-17-01-0621-g03){#f4-etm-0-0-7038}

![Pathway analysis of differentially expressed lncRNAs and mRNAs in children with HSPN. (A) Top 10 enriched pathways among the aberrantly expressed lncRNAs in the HSPN group. (B) Top 10 enriched pathways among the upregulated mRNAs in the HSPN group. (C) Top 10 pathways among all of the downregulated mRNAs. \*P\<0.05 vs. HC. lncRNA, long non-coding RNA; HSPN, Henoch-Schönlein purpura nephritis; HC, healthy controls; SNARE, soluble N-ethylmaleimide sensitive factor attachment protein receptor; TNF, tumor necrosis factor; NF-κB, nuclear factor-κB.](etm-17-01-0621-g04){#f5-etm-0-0-7038}

###### 

Clinical characteristics of 6 HSPN cases.

  Patient ID                           S64   S87   S105   S111   S173   S303
  ------------------------------------ ----- ----- ------ ------ ------ ------
  Age (years)                          14    13    10     14     11     11
  Sex                                  F     F     M      M      M      M
  Purpura                              \+    \+    \+     \+     \+     \+
  Abdominal pain                       −     \+    −      −      −      \+
  Arthralgia                           −     \+    \+     −      \+     \+
  Period between the onset of HSPN     12    10    34     16     60     20
  and initiation of therapy (months)                                    

HSPN, Henoch-Schönlein purpura nephritis; S, sick; F, female; M, male.

###### 

Primers used for reverse transcription-quantitative polymerase chain reaction.

  Gene name/direction   Sequence (5′ to 3′)      Product length (bp)
  --------------------- ------------------------ ---------------------
  ENSG00000267121                                
    F                   GAGGAAGACCCTGGAAGGAG     203
    R                   GTCCCAAGCTTCAGTCATCC     
  ENSG00000252310                                
    F                   GGTCCGAGTGTTGTGGGTTA     50
    R                   GGGGGAGACAATGTTAAATCAA   
  uc001kfc.1                                     
    F                   AAAATTAGCCAGGCATGGTG     209
    R                   TCTCTCACGGCTCTTGTGTG     
  uc010qna.2                                     
    F                   GGGTCTTCCTCATGGCACTA     202
    R                   CAGGCCTTCCAAGTTCTGAG     
  ENST00000378432                                
    F                   CCTTTTCTCCATGGCATTTG     202
    R                   TCCTGCATTCATTCATTCCA     
  ENST00000571370                                
    F                   GGTTGTTTCATTCCGCAGTT     204
    R                   TTTCTGGGACGATGAAAAGG     
  ACTB                                           
    F                   GGCCTCCAAGGAGTAAGACC     73
    R                   AGGGGAGATTCAGTGTGGTG     

F, forward; R, reverse; ACTB, β actin.

###### 

Baseline demographic and clinical data of subjects.

  Parameter                                         HSPN group (n=6)   HC group (n=4)   Normal range
  ------------------------------------------------- ------------------ ---------------- --------------
  Sex (male/female), n                              4:2                1:3              
  Age (years, mean ± SD)                            12.17±1.72         11.25±2.99       
  Serum IgA (g/l, mean ± SD)                        3.00±1.21          1.39±0.55        0.63--1.79
  Urine red blood cell count (p/µl, mean ± SD)      387.48±590.34      3.60±8.10        0-25.00
  24-h urine protein quantity (g/24 h, mean ± SD)   0.280±0.150        0.050±0.007      0--0.150

HSPN, Henoch-Schönlein purpura nephritis; HC, healthy controls; SD, standard deviation.

###### 

Top 25 aberrantly expressed lncRNAs according to the FC values between the two groups.

  lncRNA ID           FC value    P-value   Class           Database
  ------------------- ----------- --------- --------------- ----------------
  Upregulated                                               
    ENSG00000202354   736.95      0.030     Intergenic      Ensembl
    ENSG00000252310   487.59      0.007     Intergenic      Ensembl
  Downregulated                                             
    ENSG00000259001   −12971.66   0.036     Bidirectional   Ensembl
    HLA-B             −182.99     0.039     Sense           UCSC_knowngene
    ENSG00000257621   −65.40      0.012     Intronic        Ensembl
    ENSG00000262380   −44.54      0.010     Sense           Ensembl
    BC047651          −42.38      0.010     Sense           UCSC_knowngene
    ENSG00000267121   −42.31      0.002     Intergenic      Ensembl
    ENSG00000230105   −42.22      0.025     Intergenic      Ensembl
    DQ598910          −41.06      0.002     Sense           UCSC_knowngene
    ENSG00000236535   −39.99      0.020     Sense           Ensembl
    ENSG00000262879   −38.70      0.007     Intergenic      Ensembl
    BC044596          −38.50      0.034     Sense           UCSC_knowngene
    ENSG00000231485   −36.49      0.041     Intergenic      Ensembl
    ENSG00000260060   −26.54      0.045     Intergenic      Ensembl
    ENSG00000232593   −26.14      0.031     Intergenic      Ensembl
    ENSG00000246016   −24.65      0.018     Intergenic      Ensembl
    MGC72080          −24.52      0.021     Intergenic      UCSC_knowngene
    XLOC_012288       −23.80      0.036     Intergenic      TCONS
    ENSG00000247556   −21.99      0.018     Intergenic      Ensembl
    ENSG00000267672   −21.24      0.002     Sense           Ensembl
    ENSG00000227195   −19.36      0.035     Intergenic      Ensembl
    AX747098          −19.05      0.018     Sense           UCSC_knowngene
    AK098491          −18.85      0.007     Sense           UCSC_knowngene
    ENSG00000253430   −18.81      0.003     Sense           Ensembl

FC, fold-change; lncRNA, long non-coding RNA; HLA-B, human leukocyte antigen-B.

###### 

Top 25 differentially expressed mRNAs according to the FC values between the two groups.

  Gene name          Ensembl ID        FC value   P-value   Chromosome
  ------------------ ----------------- ---------- --------- ---------------------------
  Upregulated                                               
    RPL17-C18orf32   ENSG00000215472   17.16      0.026     chr18:47008027-47018906
    MNDA             ENSG00000163563   16.94      \<0.001   chr1:158801106-158819296
    IFIT1            ENSG00000185745   15.09      0.001     chr10:90973325-91174314
  Downregulated                                             
    ZNF431           ENSG00000196705   −33.88     \<0.001   chr19:21324826-21373034
    APOBR            ENSG00000184730   −29.51     0.001     chr16:28467692-28510291
    CROCC            ENSG00000058453   −29.46     0.002     chr1:17066767-17299474
    CTD-2583A14.10   ENSG00000268750   −28.25     0.002     chr19:58281022-58427978
    PAGR1            ENSG00000263136   −27.74     0.001     chr16:29262828-30215631
    KLRD1            ENSG00000134539   −25.48     \<0.001   chr12:10378656-10469850
    SYMPK            ENSG00000125755   −21.33     \<0.001   chr19:46318667-46366548
    SCT              ENSG00000070031   −21.32     0.018     chr11:626430-627143
    CEP250           ENSG00000126001   −20.73     \<0.001   chr20:34042984-34099804
    ZNF674           ENSG00000251192   −20.15     \<0.001   chrX:46357161-46404892
    GIGYF1           ENSG00000146830   −19.36     \<0.001   chr7:100277129-100287071
    ZNF814           ENSG00000204514   −18.82     \<0.001   chr19:58281022-58427978
    CEBPZ-AS1        ENSG00000218739   −18.02     \<0.001   chr2:37394962-37551951
    RABEP2           ENSG00000177548   −17.18     \<0.001   chr16:28889725-28950667
    SMARCA4          ENSG00000127616   −17.17     \<0.001   chr19:11071597-11176071
    CRIP1            ENSG00000257341   −16.97     0.004     chr14:105952653-105965912
    SULT1A3          ENSG00000261052   −16.30     0.002     chr16:29262828-30215631
    TMEM180          ENSG00000138111   −15.97     \<0.001   chr10:104221148-104236802
    CCDC88B          ENSG00000168071   −15.71     \<0.001   chr11:64107694-64125006
    TCHP             ENSG00000139437   −15.38     \<0.001   chr12:110338068-110434194
    CHCHD6           ENSG00000159685   −15.37     0.003     chr3:126423062-126679249
    BAIAP2           ENSG00000175866   −15.31     \<0.001   chr17:79008947-79156964

FC, fold-change; MNDA, myeloid nuclear differentiation antigen; IFIT1, interferon-induced protein with tetratricopeptide repeats 1; ZNF431, zinc finger protein 431; APOBR, apolipoprotein B receptor; CROCC, ciliary rootlet coiled-coil; PAGR1, PAXIP1 associated glutamate rich protein 1; KLRD1, killer cell lectin like receptor D1; SYMPK, symplekin; SCT, secretin; CEP250, centrosomal protein 250; ZNF674, zinc finger protein 674; GIGYF1, GRB10 interacting GYF protein 1; ZNF814, zinc finger protein 814; CEBPZ-AS1, CEBPZ opposite strand; RABEP2, RAB GTPase binding effector protein 2; SMARCA4, SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4; CRIP1, cysteine rich protein 1; SULT1A3, sulfotransferase family 1A member 3; TMEM180, major facilitator superfamily domain containing 13A; CCDC88B, coiled-coil domain containing 88B; TCHP, trichoplein keratin filament binding; CHCHD6, coiled-coil-helix-coiled-coil-helix domain containing 6; BAIAP2, BAI1 associated protein 2; chr, chromosome.
